Picture loading failed.

Anti-AR-C124910XX therapeutic antibody (Pre-made Bentracimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti-blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3] It is not commercially available.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-059-1mg 1mg 3090
GMP-Bios-ab-059-10mg 10mg 21890
GMP-Bios-ab-059-100mg 100mg 148000
GMP-Bios-ab-059-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-AR-C124910XX therapeutic antibody (Pre-made Bentracimab biosimilar,Whole mAb)
INN Name Bentracimab
TargetAR-C124910XX
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure5alb:HL
99% SI StructureNone
95-98% SI Structure5alc:HL
Year Proposed2020
Year Recommended2021
CompaniesMedImmune;AstraZeneca;PhaseBio
Conditions Approvedna
Conditions ActiveHaemorrhage (reversal of effects of ticagrelor)
Conditions Discontinuedna
Development Techna